Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Obstetric Labor Complications

ClinicalTrials.gov lists 3,594 trials for Obstetric Labor Complications or a narrower condition beneath it. NICHD Neonatal Research Network has the most among industry and government lead sponsors, with 41.

MeSH D007744 Urogenital Diseases C12
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 94 Phase 1/2 Phase 1/2 43 Phase 2 Phase 2 127 Phase 2/3 Phase 2/3 62 Phase 3 Phase 3 213 Phase 4 Phase 4 216 Not applicable Not applicable 1,700 Observational Observational 1,136 Phase 1 Phase 1 94 Phase 1/2 Phase 1/2 43 Phase 2 Phase 2 127 Phase 2/3 Phase 2/3 62 Phase 3 Phase 3 213 Phase 4 Phase 4 216 Not applicable Not applicable 1,700 Observational Observational 1,136

Trials per phase (log scale)

1 more section with rows

88 of the 3,594 trials are tagged with Obstetric Labor Complications itself; the rest are tagged with a narrower condition beneath it.

Get the Obstetric Labor Complications report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Obstetric Labor Complications trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 256

1990: 2 trials (Observational 1, Not applicable 1) 1991: 1 trials (Phase 2/3 1) 1992: 2 trials (Not applicable 1, Phase 3 1) 1993: 5 trials (Observational 3, Phase 3 2) 1994: 3 trials (Observational 2, Phase 2/3 1) 1995: 1 trials (Observational 1) 1996: 6 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 1/2 1, Phase 1 1) 1997: 6 trials (Observational 3, Phase 4 1, Phase 3 1, Phase 2/3 1) 1998: 6 trials (Observational 3, Not applicable 1, Phase 3 2) 1999: 7 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 2 2) 2000: 10 trials (Observational 3, Not applicable 3, Phase 3 1, Phase 2 1, Phase 1/2 2) 2001: 13 trials (Observational 1, Not applicable 5, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 1) 2002: 25 trials (Observational 5, Not applicable 8, Phase 4 4, Phase 3 3, Phase 2 1, Phase 1/2 2, Phase 1 2) 2003: 30 trials (Observational 6, Not applicable 11, Phase 4 3, Phase 3 7, Phase 2/3 1, Phase 2 2) 2004: 38 trials (Observational 5, Not applicable 15, Phase 4 5, Phase 3 6, Phase 2/3 1, Phase 2 6) 2005: 60 trials (Observational 13, Not applicable 21, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 8, Phase 1/2 2, Phase 1 3) 2006: 72 trials (Observational 16, Not applicable 29, Phase 4 7, Phase 3 9, Phase 2 7, Phase 1/2 1, Phase 1 3) 2007: 60 trials (Observational 20, Not applicable 18, Phase 4 9, Phase 3 6, Phase 2 3, Phase 1/2 2, Phase 1 2) 2008: 79 trials (Observational 31, Not applicable 21, Phase 4 6, Phase 3 9, Phase 2/3 4, Phase 2 5, Phase 1/2 1, Phase 1 2) 2009: 66 trials (Observational 27, Not applicable 23, Phase 4 4, Phase 3 4, Phase 2/3 4, Phase 1/2 1, Phase 1 3) 2010: 85 trials (Observational 29, Not applicable 31, Phase 4 8, Phase 3 7, Phase 2 6, Phase 1/2 2, Phase 1 2) 2011: 122 trials (Observational 37, Not applicable 52, Phase 4 10, Phase 3 10, Phase 2/3 2, Phase 2 4, Phase 1/2 1, Phase 1 6) 2012: 111 trials (Observational 29, Not applicable 47, Phase 4 8, Phase 3 9, Phase 2/3 2, Phase 2 10, Phase 1/2 2, Phase 1 4) 2013: 144 trials (Observational 52, Not applicable 58, Phase 4 6, Phase 3 12, Phase 2/3 3, Phase 2 5, Phase 1/2 2, Phase 1 6) 2014: 159 trials (Observational 48, Not applicable 76, Phase 4 11, Phase 3 7, Phase 2/3 5, Phase 2 9, Phase 1/2 1, Phase 1 2) 2015: 165 trials (Observational 50, Not applicable 71, Phase 4 10, Phase 3 15, Phase 2/3 4, Phase 2 4, Phase 1/2 3, Phase 1 8) 2016: 173 trials (Observational 52, Not applicable 79, Phase 4 15, Phase 3 13, Phase 2/3 4, Phase 2 6, Phase 1 4) 2017: 183 trials (Observational 62, Not applicable 93, Phase 4 12, Phase 3 8, Phase 2/3 5, Phase 1/2 1, Phase 1 2) 2018: 256 trials (Observational 77, Not applicable 133, Phase 4 19, Phase 3 12, Phase 2/3 1, Phase 2 8, Phase 1/2 2, Phase 1 4) 2019: 223 trials (Observational 81, Not applicable 110, Phase 4 8, Phase 3 8, Phase 2/3 3, Phase 2 4, Phase 1/2 3, Phase 1 6) 2020: 228 trials (Observational 88, Not applicable 114, Phase 4 6, Phase 3 4, Phase 2/3 3, Phase 2 4, Phase 1/2 1, Phase 1 8) 2021: 209 trials (Observational 72, Not applicable 112, Phase 4 8, Phase 3 8, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2022: 223 trials (Observational 71, Not applicable 126, Phase 4 8, Phase 3 3, Phase 2/3 2, Phase 2 6, Phase 1/2 2, Phase 1 5) 2023: 199 trials (Observational 58, Not applicable 109, Phase 4 13, Phase 3 3, Phase 2/3 4, Phase 2 4, Phase 1/2 2, Phase 1 6) 2024: 220 trials (Observational 66, Not applicable 125, Phase 4 9, Phase 3 10, Phase 2/3 3, Phase 2 3, Phase 1/2 1, Phase 1 3) 2025: 210 trials (Observational 68, Not applicable 107, Phase 4 14, Phase 3 7, Phase 2/3 2, Phase 2 6, Phase 1/2 1, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 172
2025 210
2024 220
2023 199
2022 223
2021 209
2020 228
2019 223
2018 256
2017 183

Forecast of the full-year count, planned starts included, not rows of this table: about 190 trials starting in 2026 and about 210 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 263 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 2,194 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Obstetric Labor Complications trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 94
Phase 1/2 43
Phase 2 127
Phase 2/3 62
Phase 3 213
Phase 4 216
Not applicable 1,700
Observational 1,136
Expanded access 3

How many Obstetric Labor Complications trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 193
Recruiting 337
Enrolling by invitation 20
Active, not recruiting 94
Completed 1,952

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Obstetric Labor Complications trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
NICHD Neonatal Research Network 41

Which drugs are being tested for Obstetric Labor Complications? (1)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
MisoprostoL 72

Interventions as named in the registry (14)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
IM Oxytocin 117
acid tranexamic 55
carbetocin 100 µg 52
Progesterone 8% 31
Nifedipine XL 27

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Obstetric Labor Complications trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Stillbirth/neonatal death 5,079 1
Patent Ductus Aretriosus 631 1
Congenital anomaly 596 2
Death 488 19
Neonatal death up to 28 days 353 1

Which publications cover Obstetric Labor Complications? (564)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (11)

MeSH descendants one level down with at least one trial, most trials first.

+1 more sub-condition

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages